A UK study on hydroxychloroquine will resume, just weeks after being halted.
The trial will see healthcare workers given the anti-malarial drug, and will continue after getting approval to proceed from the UK Medicines Agency.
Dr Siu Ping Lam, Director of Licensing at the MHRA, said: “We have reviewed the University of Oxford’s request to recommence recruitment for the ‘COPCOV’ trial, investigating the use of hydroxychloroquine in the prevention of COVID-19.
“After analysing the additional risk mitigations and consulting the Commission on Human Medicines, we have given the clinical trial the green light to recruit more participants.
“Participant safety is our priority, so we will continue to monitor the trial to ensure ongoing appropriate measures are in place to maintain continued high levels of safety.”
The drug has been promoted by Donald Trump
The news comes just three weeks after the UK halted the trial after scientists found that there was ‘no evidence of benefit’ for Covid-19 patients.
Speaking at the time, Professor Peter Horby and Professor Martin Landray, chief investigators of the trial,